ALLOGENE THERAPEUTICS INC (ALLO)
US0197701065 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 38.49M | 240K -99.38% | 95K -60.42% | 61.078K -35.71% | 43.483K -28.81% | 2.819M 6,383.05% | 55.708M 1,876.16% | 309.28M 455.18% | 520.73M 68.37% | 855M 64.19% | 1.302B 52.28% | |
| EBITDA YoY % growth | -245.34M 2.12% | -321.15M -30.90% | -300.293M 6.49% | -275.857M 8.14% | -290.809M -5.42% | -345.598M -18.84% | -321.239M 7.05% | -302.624M 5.79% | -218.943M 27.65% | -63.424M 71.03% | N/A | |
| EBIT YoY % growth | -255.79M 0.95% | -335.45M -31.14% | -314.492M 6.25% | -289.333M 8.00% | -312.405M -7.97% | -346.296M -10.85% | -351.01M -1.36% | -163.408M 53.45% | -17.505M 89.29% | 233.6M 1,434.48% | 545.13M 133.36% | |
| Operating Margin | -664.56% | -139,770.83% | -331,044.21% | -473,713.64% | -718,458.67% | -12,284.37% | -630.09% | -52.84% | -3.36% | 27.32% | 41.87% | |
| EPS YoY % growth | -1.89 9.13% | -2.32 -22.75% | -2.01 13.36% | -1.38 31.24% | -1.38 -0.14% | -1.48 -7.29% | -1.50 -1.07% | -0.36 75.81% | 0.91 350.00% | 2.16 137.83% | 3.32 53.86% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.33 22.20% | -0.33 12.20% | -0.34 2.86% | -0.34 -6.78% | -0.34 -0.33% | -0.30 11.34% | -0.30 13.00% | -0.31 10.45% | -0.31 8.84% |
| Revenue Q2Q % growth | 14.28K -32.00% | 7.936K -63.93% | 7.936K | 7.936K | 8.925K -37.50% | -100.00% | -100.00% | -100.00% | -100.00% |
| EBITDA Q2Q % growth | -69.454M 76.87% | -66.3M -0.53% | -66.3M -11.91% | -67.136M -32.58% | -67.045M 3.47% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -74.903M 76.18% | -75.458M -8.57% | -77.397M -16.49% | -78.222M -28.14% | -81.386M -8.65% | -78.03M -3.41% | -79.662M -2.93% | -81.192M -3.80% | -82.824M -1.77% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.32 13.51% | -0.34 | 0.02 | 4.75% |
| Q2 2024 Q2Q % growth | -0.35 33.96% | -0.35 | 0.00 | 1.21% |
| Q1 2024 Q2Q % growth | -0.38 44.12% | -0.42 | 0.04 | 8.99% |
| Q4 2023 Q2Q % growth | -0.43 34.85% | -0.46 | 0.03 | 6.14% |
| Q3 2023 Q2Q % growth | -0.37 36.21% | -0.53 | 0.16 | 30.17% |
| Q2 2023 Q2Q % growth | -0.53 -1.92% | -0.60 | 0.07 | 11.77% |
| Q1 2023 Q2Q % growth | -0.68 -21.43% | -0.63 | -0.05 | -8.03% |
| Q4 2022 Q2Q % growth | -0.66 -22.22% | -0.71 | 0.05 | 7.43% |
| Q3 2022 Q2Q % growth | -0.58 -1.75% | -0.66 | 0.08 | 11.76% |
| Q2 2022 Q2Q % growth | -0.52 1.89% | -0.62 | 0.10 | 16.43% |
| Q1 2022 Q2Q % growth | -0.56 -124.00% | -0.59 | 0.03 | 4.62% |
| Q4 2021 Q2Q % growth | -0.54 -1.89% | -0.61 | 0.07 | 11.52% |
| Q3 2021 Q2Q % growth | -0.57 -9.62% | -0.57 | 0.00 | 0.01% |
| Q2 2021 Q2Q % growth | -0.53 | -0.56 | 0.03 | 4.97% |
| Q1 2021 Q2Q % growth | -0.25 50.00% | -0.46 | 0.21 | 46.19% |
| Q4 2020 Q2Q % growth | -0.53 8.62% | -0.57 | 0.04 | 6.80% |
| Q3 2020 Q2Q % growth | -0.52 -4.00% | -0.55 | 0.03 | 5.21% |
| Q2 2020 Q2Q % growth | -0.53 -29.27% | -0.55 | 0.02 | 4.01% |
| Q1 2020 Q2Q % growth | -0.50 -56.25% | -0.59 | 0.09 | 15.10% |
| Q4 2019 Q2Q % growth | -0.58 | -0.70 | 0.12 | 16.77% |
| Q3 2019 Q2Q % growth | -0.50 | -0.55 | 0.05 | 8.94% |
| Q2 2019 Q2Q % growth | -0.41 | -0.47 | 0.06 | 13.18% |
| Q1 2019 Q2Q % growth | -0.32 | -0.44 | 0.12 | 26.59% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -100.00% | 13.189K | -13.189K | -100.00% |
| Q2 2024 Q2Q % growth | -100.00% | 17.248K | -17.248K | -100.00% |
| Q1 2024 Q2Q % growth | 22K -57.69% | 9.792K | 12.208K | 124.67% |
| Q4 2023 Q2Q % growth | 21K -58.00% | 24.041K | -3.041K | -12.65% |
| Q3 2023 Q2Q % growth | 43K -14.00% | 12.781K | 30.219K | 236.45% |
| Q2 2023 Q2Q % growth | 44K -51.11% | 19.268K | 24.732K | 128.36% |
| Q1 2023 Q2Q % growth | 52K -13.33% | 10.914K | 41.086K | 376.45% |
| Q4 2022 Q2Q % growth | 50K | 61.404K | -11.404K | -18.57% |
| Q3 2022 Q2Q % growth | 50K | 14.912K | 35.088K | 235.29% |
| Q2 2022 Q2Q % growth | 90K 125.00% | 5.661K | 84.339K | 1,489.83% |
| Q1 2022 Q2Q % growth | 60K -99.84% | 60K | % | |
| Q4 2021 Q2Q % growth | 50K | -6.324K | 56.324K | 890.64% |
| Q3 2021 Q2Q % growth | 50K | 14.576K | 35.424K | 243.03% |
| Q2 2021 Q2Q % growth | 40K | 235.814K | -195.814K | -83.04% |
| Q1 2021 Q2Q % growth | 38.35M | 13.102M | 25.248M | 192.70% |
| Q4 2020 Q2Q % growth | 3.23M | -3.23M | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 14.11% | -0.28% | 10.43% |
| Revenue | 0% | 9.63% | 2.13% | -6.99% |